Your browser doesn't support javascript.
loading
Drug interactions with dementia-related pathophysiological pathways worsen or prevent dementia.
Barus, Romain; Béné, Johana; Deguil, Julie; Gautier, Sophie; Bordet, Régis.
Afiliación
  • Barus R; UnivLille, INSERM, CHU Lille, Degenerative and Vascular Cognitive Disorders, Lille, France.
  • Béné J; UnivLille, INSERM, CHU Lille, Degenerative and Vascular Cognitive Disorders, Lille, France.
  • Deguil J; UnivLille, INSERM, CHU Lille, Degenerative and Vascular Cognitive Disorders, Lille, France.
  • Gautier S; UnivLille, INSERM, CHU Lille, Degenerative and Vascular Cognitive Disorders, Lille, France.
  • Bordet R; UnivLille, INSERM, CHU Lille, Degenerative and Vascular Cognitive Disorders, Lille, France.
Br J Pharmacol ; 176(18): 3413-3434, 2019 09.
Article en En | MEDLINE | ID: mdl-30714122
Many risk factors are known to induce or precipitate dementia. Drugs acting via different mechanisms can modulate cognitive performance and exert either beneficial or deleterious effects on cognition through functional or neuropathological mechanisms. This review discusses the association between several classes of drugs and cognitive impairment and dementia risk. These drugs can be divided into drugs targeting CNS disorders (e.g., anticholinergic drugs, antiepileptics, antipsychotics, benzodiazepines, and opioids) and drugs targeting non-CNS disorders (e.g., antidiabetics, antihypertensives, proton pump inhibitors, and statins). Furthermore, we sought to highlight the pharmacological mechanisms underlying their possible detrimental or beneficial effects on cognition. Anticholinergic and antiepileptic drugs were excluded from this review because their effects on cognition are well known. Studies investigating benzodiazepines have revealed an increased risk of dementia. Conclusions on dementia risk or cognitive impairment regarding opioids and antipsychotic drugs are difficult to draw. These different classes appear to impair cognition not by a single clear mechanism of action specific to each class but by several relatively interdependent and interconnected mechanisms (e.g., impaired neurotransmission, neuroinflammation, neuronal death, oxidative stress, or interactions with dementia-related pathways). The dementia risk initially associated with the use of proton pump inhibitors might have been overestimated. In contrast, statins, antihypertensive medications, and antidiabetics could potentially decrease the risk of dementia and cognitive impairment by acting in ways opposite to the mechanisms cited above. LINKED ARTICLES: This article is part of a themed section on Therapeutics for Dementia and Alzheimer's Disease: New Directions for Precision Medicine. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.18/issuetoc.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 / 6_ODS3_enfermedades_notrasmisibles Problema de salud: 1_doencas_nao_transmissiveis / 6_alzheimer_other_dementias / 6_mental_health_behavioral_disorders Asunto principal: Demencia Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Animals / Humans Idioma: En Revista: Br J Pharmacol Año: 2019 Tipo del documento: Article País de afiliación: Francia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 / 6_ODS3_enfermedades_notrasmisibles Problema de salud: 1_doencas_nao_transmissiveis / 6_alzheimer_other_dementias / 6_mental_health_behavioral_disorders Asunto principal: Demencia Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Animals / Humans Idioma: En Revista: Br J Pharmacol Año: 2019 Tipo del documento: Article País de afiliación: Francia
...